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Experimental models have demonstrated that aldosterone-induced car-
diovascular damage requires concomitant high dietary sodium exposure.
Studies from this and other laboratories have linked aldosteronism to
endothelial dysfunction and left ventricular (LV) hypertrophy in human
subjects. The current study was designed to determine if low sodium
intake can blunt aldosterone-induced endothelial dysfunction and LV
hypertrophy (LVH).
Consecutive subjects (n155) with resistant hypertension were pro-
spectively evaluated with an early morning plasma aldosterone, renin and
24-hr urinary aldosterone and sodium. Changes in brachial artery diam-
eter during hyperemia (flow-mediated dilation or FMD) were measured
as an index for endothelial function. FMD was negatively correlated and
LV end-diastolic diameter (LVDD) and LV mass (LVM) were positively
correlated with aldosterone excretion (r0.38, p0.0001 and r0.26,
p0.004). However the product of 24-hr sodium and aldosterone was an
even stronger predictor of FMD and LVH than aldosterone alone (FMD:
r-0.59, p0.0001, LVM: r0.35, p0.0001). Among subjects with
high aldosterone excretion ( 12 g/24-hr), low dietary sodium inges-
tion (100 meq/24-hr) was associated with significantly less endothelial
dysfunction and significantly less LVH. Three-month treatment with
spironolactone significantly increased FMD and decreased LVH in sub-
jects with and without aldosteronism, independent of blood pressure
reduction level. However, these improvements were significantly greater
in subjects with a high aldosterone and sodium excretion.
These results are the first demonstration that low dietary sodium
ingestion can protect from aldosterone-induced vascular and ventricular
dysfunction in humans. Further, these results suggest that cardiovascular
risk in subjects with resistant hypertension may be predicted by the
product of urinary aldosterone and sodium excretion.
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For several decades, the lack of oral availability and poor antihyperten-
sive effects of renin inhibitors (RI), despite seemingly powerful inhibition
of conventionally measured plasma renin activity (PRA), have discred-
ited RI as cardiovascular drugs. Aliskiren is a novel orally effective RI
with antihypertensive potency comparable to losartan or irbesartan. The
present study investigated the effects of aliskiren and irbesartan on PRA,
measured by the reliable antibody trapping technique, as well as on
plasma active renin concentration (ARC) and sitting systolic blood pres-
sure (SBP).
In 569 patients with mild to moderate hypertension (baseline sphyg-
momanometric sitting blood pressure 15212/994 mmHg,
meanSD), PRA and ARC, as well as SBP were measured before and
after 8 weeks of treatment with once daily oral doses of aliskiren (150,
300 or 600mg), irbesartan 150mg or placebo. The effects of study
treatments on PRA, ARC and SBP are summarized in the Table.
Aliskiren reduced PRA by 69%, 71% and 75% at 150, 300 and 600mg
respectively, while irbesartan doubled PRA. Most of the antihypertensive
effect of aliskiren was obtained with the lowest dose, but higher doses
slightly further decreased SBP. Aliskiren 150mg and irbesartan 150mg
provided similar increases in ARC and hence comparably blocked the
renin-angiotensin system (RAS), and the achieved SBP was also the
same. Aliskiren 300mg and 600mg caused greater increases in ARC
compared with irbesartan 150mg (p0.05), and further decreases in SBP.
The dose-dependent increases in ARC observed with aliskiren document
increasing blockade of the RAS.
In conclusion, aliskiren provides a parallel reduction in PRA and SBP,
a dose-dependent blockade of the RAS and is at least as effective as
irbesartan at comparable dosages (150mg).
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The aim of this study was to determine whether NAD(P)H oxidase-
inhibition could affect the soluble collagen production in control and
angiotensin II-stimulated cardiac fibroblasts. Cardiac fibroblasts from
passage 2 from normal male adult rats (n 4-6) were cultured to
confluency and incubated in serum- and phenol red-free Dulbecco’s
modified Eagle’s medium for 24 h. The cells were preincubated wth(out)
apocynin (100 mol/l) or diphenylene iodonium chloride (DPI, 1 mol/l)
for 1 h and further incubated with(out) angiotensin II (1 mol/l) for 24 h
in this medium. Soluble total collagen production was measured spec-
trophotometrically with picrosirius red as dye (Sircol assay) or by triti-
um-proline incorporation. Angiotensin II increased (p0.01) the soluble
collagen production in cardiac fibroblasts by 88.5  24.0(SEM) %.
Apocynin, which inhibits the association of p47phox and p67phox with
gp91phox within the membrane NAD(P)H oxidase complex, completely
(p0.01) blocked the angiotensin II-stimulated collagen production.
Apocynin had however no effect on the collagen production in control
fibroblasts. DPI, a cytosolic flavoprotein inhibitor of NAD(P)H oxidase,
completely blocked (p0.01) the angiotensin II-stimulated collagen pro-
duction, but did not affect the basal collagen production. The collagen
production assessed as tritium-proline incorporation was also increased
(p0.01) by angiotensin II, on average by 92.8  7.4 %. Apocynin and
DPI also blocked (p0.01 and 0.05, respectively) the angiotensin II-
stimulated tritium-proline incorporation but had no effect on the tritium-
proline incorporation in control cardiac fibroblasts. Our data show that
inhibition of the membrane-associated NAD(P)H oxidase complex with
apocynin and DPI blocks the angiotensin II-stimulated collagen produc-
tion in adult rat cardiac fibroblasts.
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Treatment N PRA (ng/mL/h) ARC (pg/mL) SBP (mmHg)
Baseline Week 8 Baseline Week 8 Baseline Week 8
Placebo 111 0.72 0.64 6.2 5.6 152  12 147  18
Aliskiren 150mg 112 0.66 0.20 6.0 15.3 151  11 140  14
Aliskiren 300mg 115 0.59 0.17 6.1 21.0 152  10 137  14
Aliskiren 600mg 113 0.64 0.16 5.8 34.9 153  12 137  16
Irbesartan 150mg 118 0.64 1.33 5.5 11.3 153  11 140  16
PRA and ARC values are geometric means; SBP values are mean  SD
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